In an interview at the 2023 DIA annual meeting with ACT editor, Andy Studna, Jean Sposaro, program lead, TransCelerate BioPharma, and director, global drug development operations industry collaborations, Bristol Myers Squibb discusses initiatives that TransCelerate is currently working on to empower patients.
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Everhart, MD, FACP, clinical vice president, internal medicine, Signant Health discusses decentralized trials and how they may be increasing site burden.
SCOPE 2024: Wendy Morahan of IQVIA Discusses the Use of AI in Clinical Trials
February 13th 2024In an interview with ACT editor Andy Studna at SCOPE, Morahan, senior director, clinical data analytics, IQVIA Technologies discusses how AI can advance trial execution and what stakeholders should be keeping top of mind when choosing technology vendors.